Section Arrow
XNCR.NASDAQ
- Xencor
Quotes are at least 15-min delayed:2026/04/15 09:41 EDT
Regular Hours
Last
 12.6
+0.09 (+0.72%)
Day High 
12.82 
Prev. Close
12.51 
1-M High
13.3 
Volume 
33.44K 
Bid
12.43
Ask
12.61
Day Low
12.6 
Open
12.65 
1-M Low
10.96 
Market Cap 
917.47M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 12.39 
20-SMA 12.15 
50-SMA 11.99 
52-W High 18.69 
52-W Low 6.92 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.24/-2.55
Enterprise Value
1.06B
Balance Sheet
Book Value Per Share
8.67
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
125.58M
Operating Revenue Per Share
1.98
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
IMMPImmutep Limited0.8886+0.5738+182.27%-- 
LIMNLiminatus Pharma Inc0.19665+0.01685+9.37%-- 
ALLOAllogene Therapeutics1.885-0.395-17.32%-- 
LNAILunai Bioworks Inc.0.2989-0.0399-11.78%-- 
RVMDRevolution Medicines149.2+2.19+1.49%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.